State Street’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

State Street’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-240,454	Closed	-$5.55M	–	4014
2020 Q4	$5.55M	Sell	240,454 -12,316	-5%	-$156K	﹤0.01%	2912
2020 Q3	$2.57M	Buy	252,770 +7,661	+3%	+$103K	﹤0.01%	3095
2020 Q2	$3.65M	Buy	245,109 +35,594	+17%	+$548K	﹤0.01%	2920
2020 Q1	$2.55M	Buy	209,515 +104,629	+100%	+$1.66M	﹤0.01%	2948
2019 Q4	$1.66M	Buy	104,886 +42,767	+69%	+$546K	﹤0.01%	3306
2019 Q3	$763K	Buy	+62,119	New	+$704K	﹤0.01%	3452

State Street's PRVL Position: Q1 2021 in Review

State Street sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 240,454 shares — an estimated $5.55M sold.

State Street first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $5.55M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

State Street reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
State Street sold 240,454 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $5.55M.
State Street first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
State Street's Prevail Therapeutics Inc. Common Stock position peaked at $5.55M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on State Street's 13F filing for Q1 2021, filed 17 May 2021.